Helicobacter pylori infection and diabetes: Is it a myth or fact?

World Journal of Gastroenterology

Volumn 20, Issue 16, 2014, Pages 4607-4617

  He, Cong ^a   Yang, Zhen ^a   Lu, Nong Hua ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Cytokines; Helicobacter pylori; Inflammation; Insulin resistance; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GASTRIN; GHRELIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOSTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; ANTIINFECTIVE AGENT; AUTACOID; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; INSULIN;

AGE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BODY MASS; CHRONIC INFLAMMATION; DIABETES MELLITUS; DYSLIPIDEMIA; GLUCOSE METABOLISM; HELICOBACTER INFECTION; HUMAN; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; META ANALYSIS (TOPIC); OBESITY; RISK FACTOR; SOCIAL STATUS; STOMACH EMPTYING; SYSTEMATIC REVIEW (TOPIC); ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PROGNOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; PROGNOSIS; RISK FACTORS;

EID: 84899650092     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i16.4607     Document Type: Article

References (172)

1. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175-1176 [PMID: 1682595]
2. Parsonnet J. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am 1993; 22: 89-104 [PMID: 8449573]
3. Malaty HM. Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 2007; 21: 205-214 [PMID: 17382273 DOI: 10.1016/j.bpg.2006.10.005]
4. Graham DY, Osato MS, Olson CA, Zhang J, Figura N. Effect of H. pylori infection and CagA status on leukocyte counts and liver function tests: extra-gastric manifestations of H. pylori infection. Helicobacter 1998; 3: 174-178 [PMID: 9731987 DOI: 10.1046/j.1523-5378.1998.08018.x]
5. Perri F, Clemente R, Festa V, De Ambrosio CC, Quitadamo M, Fusillo M, Grossi E, Andriulli A. Serum tumour necrosis factor-alpha is increased in patients with Helicobacter pylori infection and CagA antibodies. Ital J Gastroenterol Hepatol 1999; 31: 290-294 [PMID: 10425573]
6. Patel P, Mendall MA, Khulusi S, Northfield TC, Strachan DP. Helicobacter pylori infection in childhood: risk factors and effect on growth. BMJ 1994; 309: 1119-1123 [PMID: 7987103 DOI: 10.1136/bmj.309.6962.1119]
7. Eskandarian R, Ghorbani R, Shiyasi M, Momeni B, Hajifathalian K, Madani M. Prognostic role of Helicobacter pylori infection in acute coronary syndrome: a prospective cohort study. Cardiovasc J Afr 2012; 23: 131-135 [PMID: 22555636 DOI: 10.5830/CVJA-2011-016]
8. Shi WJ, Liu W, Zhou XY, Ye F, Zhang GX. Associations of Helicobacter pylori infection and cytotoxin-associated gene A status with autoimmune thyroid diseases: a meta-analysis. Thyroid 2013; 23: 1294-1300 [PMID: 23544831 DOI: 10.1089/ thy.2012.0630]
9. Monzón H, Forné M, Esteve M, Rosinach M, Loras C, Espinós JC, Viver JM, Salas A, Fernández-Bañares F. Helicobacter pylori infection as a cause of iron deficiency anaemia of unknown origin. World J Gastroenterol 2013; 19: 4166-4171 [PMID: 23864779 DOI: 10.3748/wjg.v19.i26.4166]
10. Payandeh M, Sohrabi N, Zare ME, Kansestani AN, Hashemian AH. Platelet Count Response to Helicobacter pylori Eradication in Iranian Patients with Idiopathic Thrombocytopenic Purpura. Mediterr J Hematol Infect Dis 2012; 4: e2012056 [PMID: 22973500 DOI: 10.4084/MJHID.2012.056]
11. Asadi-Pooya AA, Dehghani SM, Petramfar P, Emami M, Mahmoodi M. Helicobacter pylori infection in patients with epilepsy. Seizure 2012; 21: 21-23 [PMID: 21903421 DOI: 10.1016/j.seizure.2011.08.011]
12. Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol 2012; 19: 864-869 [PMID: 22248366 DOI: 10.1111/j.1468-1331.2011.03643.x]
13. Roubaud-Baudron C, Krolak-Salmon P, Quadrio I, Mégraud F, Salles N. Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Neurobiol Aging 2012; 33: 1009.e11-1009.e19 [PMID: 22133280 DOI: 10.1016/ j.neurobiolaging.2011.10.021]
14. Mishra RR, Tewari M, Shukla HS. Association of Helicobacter pylori infection with inflammatory cytokine expression in patients with gallbladder cancer. Indian J Gastroenterol 2013; 32: 232-235 [PMID: 23446740 DOI: 10.1007/ s12664-013-0321-6]
15. Boonyanugomol W, Chomvarin C, Sripa B, Bhudhisawasdi V, Khuntikeo N, Hahnvajanawong C, Chamsuwan A. Helicobacter pylori in Thai patients with cholangiocarcinoma and its association with biliary inflammation and proliferation. HPB (Oxford) 2012; 14: 177-184 [PMID: 22321036 DOI: 10.1111/j.1477-2574.2011.00423.x]
16. Krüttgen A, Horz HP, Weber-Heynemann J, Vucur M, Trautwein C, Haase G, Luedde T, Roderburg C. Study on the association of Helicobacter species with viral hepatitisinduced hepatocellular carcinoma. Gut Microbes 2012; 3: 228-233 [PMID: 22572832 DOI: 10.4161/gmic.19922]
17. Polyzos SA, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E, Zavos C, Anastasiadou K, Terpos E. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013; 62: 121-126 [PMID: 22841522 DOI: 10.1016/j.metabol.2012.06.007]
18. Gasbarrini A, Franceschi F, Cammarota G, Pola P, Gasbarrini G. Vascular and immunological disorders associated with Helicobacter pylori infection. Ital J Gastroenterol Hepatol 1998; 30: 115-118 [PMID: 9615278]
19. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010; 17 Suppl 1: S3-S8 [PMID: 20489418 DOI: 10.1097/01. hjr.0000368191.86614.5a]
20. Qi L, Hu FB, Hu G. Genes, environment, and interactions in prevention of type 2 diabetes: a focus on physical activity and lifestyle changes. Curr Mol Med 2008; 8: 519-532 [PMID: 18781959 DOI: 10.2174/156652408785747915]
21. Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. Int J Epidemiol 2011; 40: 804-818 [PMID: 21335614 DOI: 10.1093/ije/dyr029]
22. Papamichael KX, Papaioannou G, Karga H, Roussos A, Mantzaris GJ. Helicobacter pylori infection and endocrine disorders: is there a link? World J Gastroenterol 2009; 15: 2701-2707 [PMID: 19522019]
23. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107 [PMID: 21233852 DOI: 10.1038/nri2925]
24. Devrajani BR, Shah SZ, Soomro AA, Devrajani T. Type 2 diabetes mellitus: A risk factor for Helicobacter pylori infection: A hospital based case-control study. Int J Diabetes Dev Ctries 2010; 30: 22-26 [PMID: 20431802 DOI: 10.4103/0973-3930.60008]
25. Bener A, Micallef R, Afifi M, Derbala M, Al-Mulla HM, Usmani MA. Association between type 2 diabetes mellitus and Helicobacter pylori infection. Turk J Gastroenterol 2007; 18: 225-229 [PMID: 18080918]
26. Gulcelik NE, Kaya E, Demirbas B, Culha C, Koc G, Ozkaya M, Cakal E, Serter R, Aral Y. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. J Endocrinol Invest 2005; 28: 214-217 [PMID: 15952404]
27. Anastasios R, Goritsas C, Papamihail C, Trigidou R, Garzonis P, Ferti A. Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings. Eur J Intern Med 2002; 13: 376 [PMID: 12225782]
28. Ko GT, Chan FK, Chan WB, Sung JJ, Tsoi CL, To KF, Lai CW, Cockram CS. Helicobacter pylori infection in Chinese subjects with type 2 diabetes. Endocr Res 2001; 27: 171-177 [PMID: 11428708]
29. Stanciu OG, Trifan A, Sfarti C, Cojocariu C, Stanciu C. Helicobacter pylori infection in patients with diabetes mellitus. Rev Med Chir Soc Med Nat Iasi 2003; 107: 59-65 [PMID: 14755971]
30. Simon L, Tornóczky J, Tóth M, Jámbor M, Sudár Z. [The significance of Campylobacter pylori infection in gastroenterologic and diabetic practice]. Orv Hetil 1989; 130: 1325-1329 [PMID: 2664637]
31. Oldenburg B, Diepersloot RJ, Hoekstra JB. High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Dig Dis Sci 1996; 41: 458-461 [PMID: 8617115]
32. Quadri R, Rossi C, Catalfamo E, Masoero G, Lombardo L, Della Monica P, Rovera L, Pera A, Cavello Perin P. Helicobacter pylori infection in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2000; 10: 263-266 [PMID: 11213535]
33. Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics. Int J Cardiol 2007; 121: 229-238 [PMID: 17368586 DOI: 10.1016/ j.ijcard.2006.12.003]
34. Zhou X, Zhang C, Wu J, Zhang G. Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies. Diabetes Res Clin Pract 2013; 99: 200-208 [PMID: 23395214 DOI: 10.1016/j.diabres.2012.11.012]
35. Jeon CY, Haan MN, Cheng C, Clayton ER, Mayeda ER, Miller JW, Aiello AE. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 2012; 35: 520-525 [PMID: 22279028 DOI: 10.2337/dc11-1043]
36. Buell C, Kermah D, Davidson MB. Utility of A1C for diabetes screening in the 1999 2004 NHANES population. Diabetes Care 2007; 30: 2233-2235 [PMID: 17563338 DOI: 10.2337/ dc07-0585]
37. Herman WH, Engelgau MM, Zhang Y, Brown MB. Use of GHb (HbA(1c)) to screen for undiagnosed diabetes in the U.S. population. Diabetes Care 2000; 23: 1207-1208 [PMID: 10937532 DOI: 10.2337/diacare.23.8.1207]
38. Rohlfing CL, Little RR, Wiedmeyer HM, England JD, Madsen R, Harris MI, Flegal KM, Eberhardt MS, Goldstein DE. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care 2000; 23: 187-191 [PMID: 10868829 DOI: 10.2337/diacare.23.2.187]
39. Chen Y, Blaser MJ. Association between gastric Helicobacter pylori colonization and glycated hemoglobin levels. J Infect Dis 2012; 205: 1195-1202 [PMID: 22427676 DOI: 10.1093/ infdis/jis106]
40. Hsieh MC, Wang SS, Hsieh YT, Kuo FC, Soon MS, Wu DC. Helicobacter pylori infection associated with high HbA1c and type 2 diabetes. Eur J Clin Invest 2013; 43: 949-956 [PMID: 23879740 DOI: 10.1111/eci.12124]
41. Lutsey PL, Pankow JS, Bertoni AG, Szklo M, Folsom AR. Serological evidence of infections and Type 2 diabetes: the MultiEthnic Study of Atherosclerosis. Diabet Med 2009; 26: 149-152 [PMID: 19236617 DOI: 10.1111/ j.1464-5491.2008.02632.x]
42. Xia HH, Talley NJ, Kam EP, Young LJ, Hammer J, Horowitz M. Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol 2001; 96: 1039-1046 [PMID: 11316144 DOI: 10.1111/j.1572-0241.2001.03604.x]
43. Oluyemi A, Anomneze E, Smith S, Fasanmade O. Prevalence of a marker of active helicobacter pylori infection among patients with type 2 diabetes mellitus in Lagos, Nigeria. BMC Res Notes 2012; 5: 284 [PMID: 22686510 DOI: 10.1186/1756-0500-5-284]
44. Dore MP, Bilotta M, Malaty HM, Pacifico A, Maioli M, Graham DY, Realdi G. Diabetes mellitus and Helicobacter pylori infection. Nutrition 2000; 16: 407-410 [PMID: 10869894]
45. Demir M, Gokturk HS, Ozturk NA, Kulaksizoglu M, Serin E, Yilmaz U. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. Dig Dis Sci 2008; 53: 2646-2649 [PMID: 18320319 DOI: 10.1007/s10620-007-0185-7]
46. Bowlin SJ, Morrill BD, Nafziger AN, Lewis C, Pearson TA. Reliability and changes in validity of self-reported cardiovascular disease risk factors using dual response: the behavioral risk factor survey. J Clin Epidemiol 1996; 49: 511-517 [PMID: 8636724]
47. Borody T, Ren Z, Pang G, Clancy R. Impaired host immunity contributes to Helicobacter pylori eradication failure. Am J Gastroenterol 2002; 97: 3032-3037 [PMID: 12492186 DOI: 10.1111/j.1572-0241.2002.07121.x]
48. de Luis DA, de la Calle H, Roy G, de Argila CM, Valdezate S, Canton R, Boixeda D. Helicobacter pylori infection and insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998; 39: 143-146 [PMID: 9597384]
49. Gentile S, Turco S, Oliviero B, Torella R. The role of autonomic neuropathy as a risk factor of Helicobacter pylori infection in dyspeptic patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 1998; 42: 41-48 [PMID: 9884032]
50. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346 [PMID: 15823385 DOI: 10.1016/s0140- 6736(05)61032-x]
51. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011; 16: 79-88 [PMID: 21435084 DOI: 10.1111/j.1523-5378.2011.00822.x]
52. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter 2009; 14: 144-150 [PMID: 19751440 DOI: 10.1111/j.1523-5378.2009.00705.x]
53. Aydemir S, Bayraktaroglu T, Sert M, Sokmen C, Atmaca H, Mungan G, Gun BD, Borazan A, Ustundag Y. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci 2005; 50: 2090-2093 [PMID: 16240220 DOI: 10.1007/s10620-005-3012-z]
54. Eshraghian A, Hashemi SA, Hamidian Jahromi A, Eshraghian H, Masoompour SM, Davarpanah MA, Eshraghian K, Taghavi SA. Helicobacter pylori infection as a risk factor for insulin resistance. Dig Dis Sci 2009; 54: 1966-1970 [PMID: 19009348 DOI: 10.1007/s10620-008-0557-7]
55. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 707-713 [PMID: 1495524 DOI: 10.1056/ NEJM199209033271007]
56. Moller DE, Flier JS. Insulin resistance--mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938-948 [PMID: 1881419 DOI: 10.1056/NEJM199109263251307]
57. Gillum RF. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey. J Natl Med Assoc 2004; 96: 1470-1476 [PMID: 15586651]
58. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Kim BI, Keum DK. Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters. J Natl Med Assoc 2005; 97: 508-513 [PMID: 15868771]
59. Ricci C, Holton J, Vaira D. Diagnosis of Helicobacter pylori: invasive and non-invasive tests. Best Pract Res Clin Gastroenterol 2007; 21: 299-313 [PMID: 17382278 DOI: 10.1016/ j.bpg.2006.11.002]
60. Eshraghian A. The continuous story of Helicobacter pylori infection and insulin resistance: this time in Japan. Helicobacter 2010; 15: 160; author reply 161 [PMID: 20402819 DOI: 10.1111/j.1523-5378.2009.00741.x]
61. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894-1900 [PMID: 12089386 DOI: 10.1097/01.ASN.000001.9900.87535.43]
62. Moss SF, Legon S, Bishop AE, Polak JM, Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992; 340: 930-932 [PMID: 1357347]
63. Fernández-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2008; 19: 10-16 [PMID: 18082417 DOI: 10.1016/j.tem.2007.10.004]
64. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: 314-321 [PMID: 20588114 DOI: 10.1097/ MED.0b013e32833bf6dc]
65. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334 [PMID: 11466099 DOI: 10.1001/jama.286.3.327]
66. Vaarala O, Yki-Järvinen H. Diabetes: Should we treat infection or inflammation to prevent T2DM? Nat Rev Endocrinol 2012; 8: 323-325 [PMID: 22430880 DOI: 10.1038/nrendo. 2012.31]
67. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72: 219-246 [PMID: 20148674 DOI: 10.1146/annurev-physiol-021909-135846]
68. Liu S, Tinker L, Song Y, Rifai N, Bonds DE, Cook NR, Heiss G, Howard BV, Hotamisligil GS, Hu FB, Kuller LH, Manson JE. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med 2007; 167: 1676-1685 [PMID: 17698692 DOI: 10.1001/archinte.167.15.1676]
69. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817 [PMID: 12606524 DOI: 10.2337/ diabetes.52.3.812]
70. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801 [PMID: 16823477 DOI: 10.1172/JCI29069]
71. Fernández-Real JM, López-Bermejo A, Vendrell J, Ferri MJ, Recasens M, Ricart W. Burden of infection and insulin resistance in healthy middle-aged men. Diabetes Care 2006; 29: 1058-1064 [PMID: 16644637 DOI: 10.2337/diacare.2951058]
72. Howard BV, Best L, Comuzzie A, Ebbesson SO, Epstein SE, Fabsitz RR, Howard WJ, Silverman A, Wang H, Zhu J, Umans J. C-Reactive protein, insulin resistance, and metabolic syndrome in a population with a high burden of subclinical infection: insights from the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. Diabetes Care 2008; 31: 2312-2314 [PMID: 18796618 DOI: 10.2337/dc08-0815]
73. Misiewicz JJ. Current insights in the pathogenesis of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995; 7: 701-703 [PMID: 8590167]
74. Diomedi M, Stanzione P, Sallustio F, Leone G, Renna A, Misaggi G, Fontana C, Pasqualetti P, Pietroiusti A. Cytotoxin- associated Gene-A-positive Helicobacter pylori strains infection increases the risk of recurrent atherosclerotic stroke. Helicobacter 2008; 13: 525-531 [PMID: 19166418 DOI: 10.1111/ j.1523-5378.2008.00627.x]
75. Oshima T, Ozono R, Yano Y, Oishi Y, Teragawa H, Higashi Y, Yoshizumi M, Kambe M. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol 2005; 45: 1219-1222 [PMID: 15837252 DOI: 10.1016/j.jacc.2005.01.019]
76. Jackson L, Britton J, Lewis SA, McKeever TM, Atherton J, Fullerton D, Fogarty AW. A population-based epidemiologic study of Helicobacter pylori infection and its association with systemic inflammation. Helicobacter 2009; 14: 108-113 [PMID: 19751435 DOI: 10.1111/j.1523-5378.2009.00711.x]
77. Hamed SA, Amine NF, Galal GM, Helal SR, Tag El-Din LM, Shawky OA, Ahmed EA, Abdel Rahman MS. Vascular risks and complications in diabetes mellitus: the role of helicobacter pylori infection. J Stroke Cerebrovasc Dis 2008; 17: 86-94 [PMID: 18346651 DOI: 10.1016/j.jstrokecerebrovasdis.2007.1 0.006]
78. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119 [PMID: 15864338 DOI: 10.1172/JCI25102]
79. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50: 2384-2389 [PMID: 11574423 DOI: 10.2337/diabetes. 50.10.2384]
80. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G. Lowgrade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003; 52: 1799-1805 [PMID: 12829649 DOI: 10.2337/ diabetes.52.7.1799]
81. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-1600 [PMID: 11978661 DOI: 10.2337/diabetes. 51.5.1596]
82. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693-700 [PMID: 14988254 DOI: 10.2337/ diabetes.53.3.693]
83. Thorand B, Löwel H, Schneider A, Kolb H, Meisinger C, Fröhlich M, Koenig W. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003; 163: 93-99 [PMID: 12523922 DOI: 10.1001/ archinte.163.1.93]
84. Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-1410 [PMID: 15309290 DOI: 10.1007/s00125-004-1472-x]
85. Festa A, D'Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor- 1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137 [PMID: 11916936 DOI: 10.2337/diabetes.51.4.1131]
86. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-2021 [PMID: 12401749 DOI: 10.2337/diacare. 25.11.2016]
87. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: 1745-1751 [PMID: 12766104 DOI: 10.2337/diacare. 26.6.1745]
88. Snijder MB, Dekker JM, Visser M, Stehouwer CD, Yudkin JS, Bouter LM, Heine RJ, Nijpels G, Seidell JC. Prospective relation of C-reactive protein with type 2 diabetes: response to Han et al. Diabetes Care 2003; 26: 1656-167; author reply 1656-167; [PMID: 12716859 DOI: 10.2337/diacare.26.5.1656]
89. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factoralpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200 [PMID: 9398739 DOI: 10.1210/jcem.82.12.4450]
90. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin- 6 the link? Atherosclerosis 2000; 148: 209-214 [PMID: 10657556]
91. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992; 52: 4113-4116 [PMID: 1638523]
92. Berg M, Fraker DL, Alexander HR. Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes. Cytokine 1994; 6: 425-432 [PMID: 7948751]
93. Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousos GP. The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 1999; 84: 2126-2133 [PMID: 10372721 DOI: 10.1210/jcem.84.6.5747]
94. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity- linked insulin resistance. Science 1993; 259: 87-91 [PMID: 7678183 DOI: 10.1126/science.7678183]
95. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010; 31: 817-844 [PMID: 20592272 DOI: 10.1210/er.2009-0030]
96. Lassenius MI, Pietiläinen KH, Kaartinen K, Pussinen PJ, Syrjänen J, Forsblom C, Pörsti I, Rissanen A, Kaprio J, Mustonen J, Groop PH, Lehto M. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011; 34: 1809-1815 [PMID: 21636801 DOI: 10.2337/dc10-2197]
97. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204 [PMID: 10903648 DOI: 10.1136/bmj.321.7255.199]
98. Ridker PM, Danesh J, Youngman L, Collins R, Stampfer MJ, Peto R, Hennekens CH. A prospective study of Helicobacter pylori seropositivity and the risk for future myocardial infarction among socioeconomically similar U.S. men. Ann Intern Med 2001; 135: 184-188 [PMID: 11487485 DOI: 10.7326 /0003-4819-135-3-200108070-00010]
99. Jeffery PL, McGuckin MA, Linden SK. Endocrine impact of Helicobacter pylori: focus on ghrelin and ghrelin o-acyltransferase. World J Gastroenterol 2011; 17: 1249-1260 [PMID: 21455323 DOI: 10.3748/wjg.v17.i10.1249]
100. Roper J, Francois F, Shue PL, Mourad MS, Pei Z, Olivares de Perez AZ, Perez-Perez GI, Tseng CH, Blaser MJ. Leptin and ghrelin in relation to Helicobacter pylori status in adult males. J Clin Endocrinol Metab 2008; 93: 2350-2357 [PMID: 18397989 DOI: 10.1210/jc.2007-2057]
101. Kaneko H, Konagaya T, Kusugami K. Helicobacter pylori and gut hormones. J Gastroenterol 2002; 37: 77-86 [PMID: 11871770]
102. Peach HG, Barnett NE. Helicobacter pylori infection and fasting plasma glucose concentration. J Clin Pathol 2001; 54: 466-469 [PMID: 11376021 DOI: 10.1136/jcp.54.6.466]
103. Rehfeld JF, Stadil F. The effect of gastrin on basal- and glucose- stimulated insulin secretion in man. J Clin Invest 1973; 52: 1415-1426 [PMID: 4703228 DOI: 10.1172/JCI107315]
104. Açbay O, Celik AF, Gündoǧdu S. Does Helicobacter pyloriinduced gastritis enhance food-stimulated insulin release? Dig Dis Sci 1996; 41: 1327-1331 [PMID: 8689907]
105. Colturi TJ, Unger RH, Feldman M. Role of circulating somatostatin in regulation of gastric acid secretion, gastrin release, and islet cell function. Studies in healthy subjects and duodenal ulcer patients. J Clin Invest 1984; 74: 417-423 [PMID: 6146638 DOI: 10.1172/JCI111437]
106. Calam J. Helicobacter pylori modulation of gastric acid. Yale J Biol Med 1999; 72: 195-202 [PMID: 10780581]
107. Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG. Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996; 98: 1101-1106 [PMID: 8787671 DOI: 10.1172/JCI118891]
108. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001; 50: 227-232 [PMID: 11272130 DOI: 10.2337/diabetes.50.2.227]
109. Williams J, Mobarhan S. A critical interaction: leptin and ghrelin. Nutr Rev 2003; 61: 391-393 [PMID: 14677575 DOI: 10.1301/nr.2003.nov.391-393]
110. Verhulst PJ, Depoortere I. Ghrelin's second life: from appetite stimulator to glucose regulator. World J Gastroenterol 2012; 18: 3183-3195 [PMID: 22783041 DOI: 10.3748/wjg.v18. i25.3183]
111. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol 2008; 103: 3005-3010 [PMID: 19086952 DOI: 10.1111/j.1572-0241.2008.02151.x]
112. Isomoto H, Ueno H, Nishi Y, Wen CY, Nakazato M, Kohno S. Impact of Helicobacter pylori infection on ghrelin and various neuroendocrine hormones in plasma. World J Gastroenterol 2005; 11: 1644-1648 [PMID: 15786542]
113. Nwokolo CU, Freshwater DA, O'Hare P, Randeva HS. Plasma ghrelin following cure of Helicobacter pylori. Gut 2003; 52: 637-640 [PMID: 12692045 DOI: 10.1136/gut.52.5.637]
114. Francois F, Roper J, Joseph N, Pei Z, Chhada A, Shak JR, de Perez AZ, Perez-Perez GI, Blaser MJ. The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol 2011; 11: 37 [PMID: 21489301 DOI: 10.1186/1471-230X-11-37]
115. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-913 [PMID: 11057670 DOI: 10.1038/35038090]
116. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weightreducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-546 [PMID: 7624777 DOI: 10.1126/science.7624777]
117. Osawa H, Nakazato M, Date Y, Kita H, Ohnishi H, Ueno H, Shiiya T, Satoh K, Ishino Y, Sugano K. Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab 2005; 90: 10-16 [PMID: 15483107 DOI: 10.1210/jc.2004-1330]
118. Osawa H. Ghrelin and Helicobacter pylori infection. World J Gastroenterol 2008; 14: 6327-6333 [PMID: 19009647]
119. Nishi Y, Isomoto H, Uotani S, Wen CY, Shikuwa S, Ohnita K, Mizuta Y, Kawaguchi A, Inoue K, Kohno S. Enhanced production of leptin in gastric fundic mucosa with Helicobacter pylori infection. World J Gastroenterol 2005; 11: 695-699 [PMID: 15655824]
120. Pöykkö SM, Kellokoski E, Hörkkö S, Kauma H, Kesäniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546-2553 [PMID: 14514639 DOI: 10.2337/diabetes.52.10.2546]
121. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 1185-1188 [PMID: 8895466 DOI: 10.1126/science.274.5290.1185]
122. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 988-991 [PMID: 8666154]
123. Fischer S, Hanefeld M, Haffner SM, Fusch C, Schwanebeck U, Köhler C, Fücker K, Julius U. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol 2002; 39: 105-110 [PMID: 12357293 DOI: 10.1007/s005920200027]
124. Guldstrand M, Ahrén B, Adamson U. Improved betacell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab 2003; 284: E557-E565 [PMID: 12556352 DOI: 10.1152/ajpendo. 00325.2002]
125. Hennige AM, Stefan N, Kapp K, Lehmann R, Weigert C, Beck A, Moeschel K, Mushack J, Schleicher E, Häring HU. Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. FASEB J 2006; 20: 1206-1208 [PMID: 16611834 DOI: 10.1096/fj.05- 4635fje]
126. Maedler K, Schulthess FT, Bielman C, Berney T, Bonny C, Prentki M, Donath MY, Roduit R. Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases. FASEB J 2008; 22: 1905-1913 [PMID: 18263705 DOI: 10.1096/fj.07-101824]
127. Brown JE, Dunmore SJ. Leptin decreases apoptosis and alters BCL-2: Bax ratio in clonal rodent pancreatic beta-cells. Diabetes Metab Res Rev 2007; 23: 497-502 [PMID: 17318810 DOI: 10.1002/dmrr.726]
128. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794 [PMID: 10491414 DOI: 10.1172/JCI7231]
129. So WY, Tong PC, Ko GT, Ma RC, Ozaki R, Kong AP, Yang X, Ho CS, Lam CC, Chan JC. Low plasma adiponectin level, white blood cell count and Helicobacter pylori titre independently predict abnormal pancreatic beta-cell function. Diabetes Res Clin Pract 2009; 86: 89-95 [PMID: 19747747 DOI: 10.1016/j.diabres.2009.08.010]
130. Rahman MA, Cope MB, Sarker SA, Garvey WT, Chaudhury HS, Khaled MA. Helicobacter pylori Infection and Inflammation: Implication for the Pathophysiology of Diabetes and Coronary Heart Disease in Asian Indians. J. Life Sci 2009; 1: 45-50 [PMID: 22308070]
131. Fosslien E. Mitochondrial medicine--molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci 2001; 31: 25-67 [PMID: 11314862]
132. Lee YH, Magkos F, Mantzoros CS, Kang ES. Effects of leptin and adiponectin on pancreatic β-cell function. Metabolism 2011; 60: 1664-1672 [PMID: 21632069 DOI: 10.1016/ j.metabol.2011.04.008]
133. Wang C, Guan Y, Yang J. Cytokines in the Progression of Pancreatic β-Cell Dysfunction. Int J Endocrinol 2010; 2010: 515136 [PMID: 21113299 DOI: 10.1155/2010/515136]
134. Omori K, Mitsuhashi M, Ishiyama K, Nair I, Rawson J, Todorov I, Kandeel F, Mullen Y. mRNA of the pro-apoptotic gene BBC3 serves as a molecular marker for TNF-α-induced islet damage in humans. Diabetologia 2011; 54: 2056-2066 [PMID: 21567299 DOI: 10.1007/s00125-011-2183-8]
135. Wada Y, Hamamoto Y, Kawasaki Y, Honjo S, Fujimoto K, Tatsuoka H, Matsuoka A, Ikeda H, Fujikawa J, Koshiyama H. The Eradication of Helicobacter pylori does not Affect Glycemic Control in Japanese Subjects with Type 2 Diabetes. Jpn Clin Med 2013; 4: 41-43 [PMID: 23966817 DOI: 10.4137/JCM. S10828]
136. Zojaji H, Ataei E, Sherafat SJ, Ghobakhlou M, SR F. The effect of the treatment of Helicobacter pylori infection on the glycemic control in type 2 diabetes mellitus. Gastroenterol Hepatol Bed Bench 2013; 6: 36-40
137. Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and lowgrade inflammation. South Med J 2010; 103: 190-196 [PMID: 20134372 DOI: 10.1097/SMJ.0b013e3181cf373f]
138. Vafaeimanesh J, Rajabzadeh R, Ahmadi A, Moshtaghi M, Banikarim S, Hajiebrahimi S, Seyyedmajidi M. Effect of Helicobacter pylori eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens. Arab J Gastroenterol 2013; 14: 55-58 [PMID: 23820501 DOI: 10.1016/j.ajg.2013.03.002]
139. Mozaffarian D, Kamineni A, Carnethon M, Djoussé L, Mukamal KJ, Siscovick D. Lifestyle risk factors and new-onset diabetes mellitus in older adults: the cardiovascular health study. Arch Intern Med 2009; 169: 798-807 [PMID: 19398692 DOI: 10.1001/archinternmed.2009.21]
140. Ojetti V, Pellicano R, Fagoonee S, Migneco A, Berrutti M, Gasbarrini A. Helicobacter pylori infection and diabetes. Minerva Med 2010; 101: 115-119 [PMID: 20467410]
141. Burghen GA, Murrell LR, Whitington GL, Klyce MK, Burstein S. Acid peptic disease in children with type I diabetes mellitus. A complicating relationship. Am J Dis Child 1992; 146: 718-722 [PMID: 1595627]
142. Chang J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis and its impact on glycemia. Endocrinol Metab Clin North Am 2010; 39: 745-762 [PMID: 21095542 DOI: 10.1016/ j.ecl.2010.08.007]
143. Jones KL, Wishart JM, Berry M, Russo A, Xia HH, Talley NJ, Horowitz M. Helicobacter pylori infection is not associated with delayed gastric emptying or upper gastrointestinal symptoms in diabetes mellitus. Dig Dis Sci 2002; 47: 704-709 [PMID: 11991596]
144. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Comment on: Jeon et al. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes. Diabetes Care 2012; 35: 520-525. Diabetes Care 2012; 35: e53; author reply e54 [PMID: 22723589 DOI: 10.2337/dc12-0248]
145. Astrup A, Finer N. Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obes Rev 2000; 1: 57-59 [PMID: 12119987 DOI: 10.1046/j.1467-789x.2000.00013. x]
146. Perdichizzi G, Bottari M, Pallio S, Fera MT, Carbone M, Barresi G. Gastric infection by Helicobacter pylori and antral gastritis in hyperglycemic obese and in diabetic subjects. New Microbiol 1996; 19: 149-154 [PMID: 8722311]
147. Cohen D, Muhsen K. Association between Helicobacter pylori colonization and glycated hemoglobin levels: is this another reason to eradicate H. pylori in adulthood? J Infect Dis 2012; 205: 1183-1185 [PMID: 22427675 DOI: 10.1093/infdis/ jis110]
148. Ioannou GN, Weiss NS, Kearney DJ. Is Helicobacter pylori seropositivity related to body mass index in the United States? Aliment Pharmacol Ther 2005; 21: 765-772 [PMID: 15771763 DOI: 10.1111/j.1365-2036.2005.02369.x]
149. Cho I, Blaser MJ, François F, Mathew JP, Ye XY, Goldberg JD, Bini EJ. Helicobacter pylori and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2005; 162: 579-584 [PMID: 16093294 DOI: 10.1093/aje/kwi237]
150. Wu MS, Lee WJ, Wang HH, Huang SP, Lin JT. A casecontrol study of association of Helicobacter pylori infection with morbid obesity in Taiwan. Arch Intern Med 2005; 165: 1552-1555 [PMID: 16009873 DOI: 10.1001/ archinte.165.13.1552]
151. Fujiwara Y, Higuchi K, Arafa UA, Uchida T, Tominaga K, Watanabe T, Arakawa T. Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. Hepatogastroenterology 2002; 49: 1298-1302 [PMID: 12239930]
152. Kamada T, Hata J, Kusunoki H, Ito M, Tanaka S, Kawamura Y, Chayama K, Haruma K. Eradication of Helicobacter pylori increases the incidence of hyperlipidaemia and obesity in peptic ulcer patients. Dig Liver Dis 2005; 37: 39-43 [PMID: 15702858 DOI: 10.1016/j.dld.2004.07.017]
153. Konturek PC, Cześnikiewicz-Guzik M, Bielanski W, Konturek SJ. Involvement of Helicobacter pylori infection in neurohormonal control of food intake. J Physiol Pharmacol 2006; 57 Suppl 5: 67-81 [PMID: 17218760]
154. Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 2001; 86: 965-971 [PMID: 11238470]
155. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006; 35: 491-510, vii-viii [PMID: 16959582 DOI: 10.1016/j.ecl.2006.06.002]
156. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-749 [PMID: 12774165 DOI: 10.1007/s00125-003-1111-y]
157. Majka J, Róg T, Konturek PC, Konturek SJ, Bielański W, Kowalsky M, Szczudlik A. Influence of chronic Helicobacter pylori infection on ischemic cerebral stroke risk factors. Med Sci Monit 2002; 8: CR675-CR684 [PMID: 12388919]
158. Chimienti G, Russo F, Lamanuzzi BL, Nardulli M, Messa C, Di Leo A, Correale M, Giannuzzi V, Pepe G. Helicobacter pylori is associated with modified lipid profile: impact on Lipoprotein(a). Clin Biochem 2003; 36: 359-365 [PMID: 12849867]
159. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis 1999; 142: 207-210 [PMID: 9920523]
160. Hoffmeister A, Rothenbacher D, Bode G, Persson K, März W, Nauck MA, Brenner H, Hombach V, Koenig W. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol 2001; 21: 427-432 [PMID: 11231924]
161. Takashima T, Adachi K, Kawamura A, Yuki M, Fujishiro H, Rumi MA, Ishihara S, Watanabe M, Kinoshita Y. Cardiovascular risk factors in subjects with Helicobacter pylori infection. Helicobacter 2002; 7: 86-90 [PMID: 11966866]
162. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992; 41 Suppl 2: 97-101 [PMID: 1526345]
163. Ando TMM, Ishiguro K, Maeda O, Watanabe O, Mizuno T, Fujita T, Takahashi H, Noshiro M, Goto H. Changes in biochemical parameters related to atherosclerosis after Helicobacter pylori eradication. Aliment Pharmaco Ther 2006; 24 Suppl 4: 58-64 [DOI: 10.1111/j.1365-2036.2006.00026.x]
164. Elizalde JI, Piqué JM, Moreno V, Morillas JD, Elizalde I, Bujanda L, De Argila CM, Cosme A, Castiella A, Ros E. Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. Aliment Pharmacol Ther 2002; 16: 577-586 [PMID: 11876713 DOI: 10.1046/ j.1365-2036.2002.01202.x]
165. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 2009; 119: 2475-2487 [PMID: 19729845 DOI: 10.1172/ JCI38605]
166. Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med 2007; 167: 821-827 [PMID: 17452546 DOI: 10.1001/archinte.167.8.821]
167. Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis 2008; 198: 553-560 [PMID: 18598192 DOI: 10.1086/590158]
168. Perry S, de Jong BC, Solnick JV, de la Luz Sanchez M, Yang S, Lin PL, Hansen LM, Talat N, Hill PC, Hussain R, Adegbola RA, Flynn J, Canfield D, Parsonnet J. Infection with Helicobacter pylori is associated with protection against tuberculosis. PLoS One 2010; 5: e8804 [PMID: 20098711 DOI: 10.1371/journal.pone.0008804]
169. Rothenbacher D, Blaser MJ, Bode G, Brenner H. Inverse relationship between gastric colonization of Helicobacter pylori and diarrheal illnesses in children: results of a populationbased cross-sectional study. J Infect Dis 2000; 182: 1446-1449 [PMID: 11015236 DOI: 10.1086/315887]
170. de Martel C, Llosa AE, Farr SM, Friedman GD, Vogelman JH, Orentreich N, Corley DA, Parsonnet J. Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis 2005; 191: 761-767 [PMID: 15688293 DOI: 10.1086/427659]
171. Vaezi MF, Falk GW, Peek RM, Vicari JJ, Goldblum JR, Perez- Perez GI, Rice TW, Blaser MJ, Richter JE. CagA-positive strains of Helicobacter pylori may protect against Barrett' s esophagus. Am J Gastroenterol 2000; 95: 2206-2211 [PMID: 11007219 DOI: 10.1111/j.1572-0241.2000.02305.x]
172. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyrén O. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004; 96: 388-396 [PMID: 14996860 DOI: 10.1093/jnci/djh057]